Abstract:Background: Cancer resistance to chemotherapy arises from various genetic and epigenetic changes that promote malignant cell proliferation. The emergence of CRISPR-Cas9, a highly adaptable genome-editing tool, is revolutionizing cancer modeling by facilitating the precise generation of desired genetic mutations. Objective: This study explores the efficacy of CRISPR-Cas9 in developing cellular and animal cancer models, correcting oncogenic mutations, and advancing cancer therapeutics through gene editing. Methods: The CRISPR-Cas9 system was employed to introduce specific genetic alterations in cellular and animal models. These models were then used to simulate the complex interactions within tumors and to test the effectiveness of gene edits in mitigating cancer traits. Results: Findings reveal that CRISPR-Cas9 enhanced the precision of anti-cancer treatments, with a significant reduction in tumor viability by up to 60% in treated models. Additionally, genetic corrections of mutated oncogenes achieved an efficiency of approximately 70%, underscoring the potential of CRISPR-Cas9 in targeted cancer therapy. Conclusion: CRISPR-Cas9 has proven to be a powerful tool for cancer research, offering new avenues for the development of advanced therapeutic strategies. Its ability to modify genetic makeup efficiently holds promise for its integration into clinical settings, though challenges in safety and delivery remain.

Towards Personalized Cancer Care: A Report of CRISPR-Cas9 Applications in Targeted Therapies and Precision Medicine